Articolo L’altra medicina N. 107 – 07/2021
Bibliografia
1 https://www.israelnationalnews.com/News/News.aspx/304124
2 Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S Epidemiology of COVID-19 Among Children in China. Pediatrics. 2020;145(6) Epub 2020 Mar 16
3 Shim, E., Tariq, A., Choi, W., Lee, Y. & Chowell, G. Transmission potential and severity of COVID-19 in South Korea. Int. J. Infect. Dis. 93, 339–344 (2020)
4 Cereda, D. et al. The early phase of the COVID-19 outbreak in Lombardy, Italy. Preprintat https://arxiv.org/pdf/2003.09320.pdf (2020)
5 Sun, K., Chen, J. & Viboud, C. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit. Health 2, e201–e208 (2020).
6 Liguoro et al., SARS-CoV-2 infection in children and newborns: a systematic review, J. Pediatr., 2020 Jul, 179(7):10291046, doi: 10.1007/s00431-020-03684-7
7 CDC COVID-19 Response Team Coronavirus Disease 2019 in Children – United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422. Epub 2020 Apr 10.
8 Gruppo di Lavoro su COVID-19 in Pediatria della Regione Emilia-Romagna (RE-CO-PED) Gestione del COVID-19 in età pediatrica: documento di consenso Medico e Bambino 2021;40(2):85-10 doi: https://doi.org/10.53126/MEB40085 9 Davies, N.G., Klepac, P., Liu, Y. et al. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med 26, 1205–1211 (2020). https://doi.org/10.1038/s41591-020-0962-9
10 European Centre for Disease Prevention and Control. COVID-19 testing strategies and objectives. 15 September ECDC:Stockholm; 2020. https://www.ecdc.europa.eu/en/publications-data/covid-19-testing-strategies-and objectives
11 IRCCS Medicina di genere e COVID-19 Luglio 2020
12 Ludvigsson J. F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults, Acta Paediatr., 2020 Jun, 109(6):1088-1095, doi: 10.1111/apa.15270
13 Indicazioni ad interim per gravidanza, parto, allattamento e cura dei piccolissimi di 0-2 anni in risposta all’emergenza COVID-19. Aggiornamento del Rapporto ISS COVID-19 n. 45/2020 Versione del 5 febbraio 2021
14 Ministero della salute Medicina di genere e COVID-19 Luglio 2020
15 Deville JG. Coronavirus disease 2019 (COVID-19): Clinical manifestations and diagnosis in children. UpToDate aggiornato 19.01.2021 https://www.uptodate.com/contents/coronavirus-disease-2019-covid-19-clinical-manifestations-and-diagnosis-in-children?topicRef=127454&source=see_link.
16 European Centre for Disease Prevention and Control. COVID-19 in children and the role of school settings in transmission – first update (23 december). Stockholm, 2020.
17 Li X, Xu W, Dozier M, et al.; UNCOVER. The role of children in transmission of SARS-CoV-2:A rapid review. J Glob Health 2020;10: 011101
18 Munro APS, Faust SN. Children are not COVID-19 super spreaders: time to go back to school. Arch Dis Child 2020;105:618-9
19 Lee B, Raszka W COVID-19 Transmission and Children: The Child Is Not to Blame DOI: 10.1542/peds.2020-004879
20 Alasdair P S Munro Children are not COVID-19 super spreaders: time to go back to school http://dx.doi.org/10.1136/archdischild-2020-319474
21 Klara M Posfay-Barbe COVID-19 in Children and the Dynamics of Infection in Families Pediatrics 2020 Aug;146(2):e20201576. doi: 10.1542/peds.2020-1576. Epub 2020 May 26.
22 Zhu Y, Bloxham CJ,Hulme KD , et al. Children are unlikely to have been the primary source of household SARS-CoV-2 infections. SSRN Journal 2020. doi:doi:10.1101/2020.03.26.20044826.
23 Bellavite P and Donzelli A. Adverse events following measles-mumps-rubella-varicella vaccine: an independent per- spective on Italian pharmacovigilance data [version 2; peer review: 2 approved]. F1000Research 2021, 9:1176 (https://doi.org/10.12688/f1000research.26523.2)
24 Mohammad Mahmudur Rahman Maruf Hasan Asif Ahmed Potential detrimental role of soluble ACE2 in severe COVID‐19 comorbid patients Medical Virology First published: 10 January 2021 https://doi.org/10.1002/rmv.2213
25 Sol M Cancel Tirado, Kyoung-Jin Yoon Antibody-dependent enhancement of virus infection and disease Viral Immu- nol . 2003;16(1):69-86. doi: 10.1089/088282403763635465.
26 Stephen Obaro COVID-19 herd immunity by immunisation: are children in the herd? Lancet Infect Dis 2021 Pub- lished Online April 19, 2021 https://doi.org/10.1016/ S1473-3099(21)00212-7
27 Isaac See, John R. Su, et al US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021 JAMA. Published online April 30, 2021. doi:10.1001/jama.2021.7517
28JamesLyons-Weiler Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity Journal of Translational Autoimmunity Volume 3, 2020, 100051 https://doi.org/10.1016/j.jtauto.2020.100051
30 Tinari S The EMA covid-19 data leak, and what it tells us about mRNA instability BMJ 2021;372:n627
31 http://www.quotidianosanita.it/scienza-e-farmaci/articolo.php?articolo_id=93964
32 WHO Background document on the Janssen Ad26.COV2.S (COVID-19) vaccine Background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine 17 March 2021
35 Almubaid Z, Al-Mubaid H.CoV-2. Gene Rep. 2021 Jun;23:101064. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917442/
36 CORRESPONDENCE Neutralizing Activity of BNT162b2-Elicited Serum N Engl J Med 2021; 384:1466-1468 DOI: 10.1056/NEJMc2102017
37 Wang, P., Nair, M.S., Liu, L. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature (2021). https://doi.org/10.1038/s41586-021-03398-2
39 Shabir A. Madhi, et all Efficacy of the ChAdOx1 nCoV-19 COVID-19 Vaccine against the B.1.351 Variant NEJM March 16, 2021 DOI: 10.1056/NEJMoa2102214
40 CORRESPONDENCE Neutralizing Activity of BNT162b2-Elicited Serum N Engl J Med 2021; 384:1466-1468 DOI: 10.1056/NEJMc2102017
41 Wang, P., Nair, M.S., Liu, L. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature (2021). https://doi.org/10.1038/s41586-021-03398-2
42 Thompson MG, Burgess JL, Naleway AL, et al. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA- 1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 2021;70:495–500. DOI: http://dx.doi.org/10.15585/mmwr.mm7013e3
43 Talia Kustin et all Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals medRxiv preprint doi: https://doi.org/10.1101/2021.04.06.21254882
44 Merryn Voysey, et all Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an inter- im analysis of four randomised controlled trials in Brazil, South Africa, and the UK The Lancet VOLUME 397, ISSUE 10269, P99-111, JANUARY 09, 2021
45 Talia Kustin et all Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals medRxiv preprint doi: https://doi.org/10.1101/2021.04.06.21254882
46 https://www.nature.com/articles/d41586-021-00396-2
47 Ioannidis JPA. Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic. Eur J Clin Invest. 2020; 50(12):e13423
48 Stefan Pilz et all. SARS‐CoV‐2 re‐infection risk in Austria https://doi.org/10.1111/eci.13520
49 Richard Horton Offline: COVID-19 is not a pandemic The Lancet :September 26, 2020
DOI:https://doi.org/10.1016/S0140-6736(20)32000-6 https://fondazioneallinearesanitaesalute.org/2020/10/provvedimenti-alla-portata-di-chiunque-per-potenziare-la- salute/
51 UN Policy Brief: The Impact of COVID-19 on children, 15 April 2020
